Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Avalo Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 9 filings
- 3 insiders, $2.04M in total
- Insiders trading
- 3
- Net value
- −$2.04M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Avalo Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | 39,900 | Sep 18, 2026 | 12 |
| Doyle Mittie | Chief Medical Officer | 51,776 | Sep 1, 2026 | 16 |
| Riley Jennifer | Chief Strategy Officer | 37,041 | Aug 12, 2026 | 5 |
| Philip Ron M | Director | – | Jul 2, 2026 | 2 |
| Lind Kevin Robert | Director | – | Jul 2, 2026 | 5 |
| Jain Rita | Director | – | Jul 2, 2026 | 5 |
| Varki Paul | Chief Legal Officer | 32,576 | Jun 12, 2026 | 5 |
| Kaplan Gilla | Director | 6,333 | Jun 4, 2026 | 2 |
| Heffernan Michael Thomas | Director | – | Jun 4, 2026 | 1 |
| Kantoff Aaron | Director | 6,333 | Jun 4, 2026 | 2 |
| Truex Samantha | Director | 6,333 | Jun 4, 2026 | 2 |
| Neil Garry Arthur | Chief Executive Officer | 190,314 | May 26, 2026 | 3 |
| Chan Mitchell | Director | 3,166 | May 7, 2026 | 2 |
| Goldman Jonathan | Director | 3,166 | Mar 31, 2026 | 2 |
| Boyd Taylor | Chief Business Officer | – | Mar 2, 2026 | 2 |
| Almenoff June Sherie | Director | 3,167 | Jun 18, 2025 | 0 |
| Persson Magnus | Director | – | Dec 21, 2023 | 0 |
| Armistice Capital, LLC | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Armistice Capital Master Fund Ltd. | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Boyd Steven | 10% Owner | 731,458Indirect | Jun 28, 2023 | 0 |
| Caissa Capital Management ltd. | 10% Owner | 0 | Jun 27, 2023 | 0 |
| Miller Joseph M | Director | – | Apr 4, 2022 | 0 |
| Smolinski Stephen | Chief Commercial Officer | – | Jan 6, 2022 | 0 |
| Harrell James Archie Jr | Chief Commercial Officer | 36,766 | Dec 14, 2021 | 0 |
| Wilkins H Jeffrey | Chief Medical Officer | 33,373 | Dec 14, 2021 | 0 |
| Greenway Schond L. | CFO | 3,883 | Dec 14, 2021 | 0 |
| Gutry Phil | Director | – | Dec 3, 2021 | 0 |
| Bruhn Suzanne Louise | Director | – | Nov 12, 2021 | 0 |
| Cola Michael F | Chief Executive Officer | – | Oct 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.45K | $18.00 | −$26.1K | −2.7%51.8K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jun 30 | 2 days | Doyle MittieChief Medical Officer | SSale | −4.65K | $20.00 | −$93.1K | −8.2%51.8K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:05 PM ET | Jul 27 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.00K | $20.00 | −$20.0K | −1.9%51.8K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:10 PM ET | Aug 10 | 2 days | Doyle MittieChief Medical Officer | SSale | −679 | $20.00 | −$13.6K | −1.3%51.8K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:10 PM ET | Aug 11 | 1 day | Riley JenniferChief Strategy Officer | SSale | −2.65K | $19.59 | −$52.0K | −6.7%37.0K after | |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.00K | $20.00 | −$20.0K | −1.9%51.8K after | 10b5-1 |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17-18 | 2 days | Sullivan Christopher RyanChief Financial Officer | SSale | −72.7K | $19.94 | −$1.45M | −64.6%39.9K after | 3 lots10b5-1 |
| Sep 1, 2026 (view filing)4:38 PM ET | Aug 28 | 4 days | Doyle MittieChief Medical Officer | SSale | −679 | $20.00 | −$13.6K | −1.3%51.8K after | 10b5-1 |
| Sep 11, 2026 (view filing)4:10 PM ET | Sep 10 | 1 day | Sullivan Christopher RyanChief Financial Officer | SSale | −10.2K | $17.62 | −$179.5K | −20.3%39.9K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:10 PM ET | Sep 16 | 2 days | Sullivan Christopher RyanChief Financial Officer | SSale | −12.4K | $16.33 | −$202.4K | −23.7%39.9K after | 10b5-1 |